Celgene racks up third Otezla approval, heating up talks about who Bristol-Myers will sell to
Whoever is taking Otezla off Bristol-Myers Squibb’s hands will have one more revenue stream to boast.
The drug — a rising star in Celgene’s pipeline that generated global sales of $1.6 billion last year — is now OK’d to treat oral ulcers associated with Behçet’s disease, a common symptom for a rare inflammatory disorder. This marks the third FDA approval for the PDE4 inhibitor since 2014, when it was greenlighted for plaque psoriasis and psoriatic arthritis.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 85,300+ biopharma pros reading Endpoints daily — and it's free.